An interim analysis of a phase II/III prospective randomized, multicenter, controlled trial of the hepatassist® bioartificial liver support system for the treatment of fulminant hepatic failure: Anthony C Stevens, Circe Biomed, Lexington, MA; R Busuttil, S Han, A Baquerizo, UCLA, Los Angeles, CA; J Fair, R Shrestha, M Johnson, UNC Sch of Medicine, Chapel Hill, NC; J Bloomer, B McGuire, Univ of Alabama, Birmingham, AL; P Rosenthal, N Ascher, C Freise, UCSF, San Francisco, CA; F Watanabe, Cedars Sinai Medical Ctr, Los Angeles, CA; X Rogiers, J Schulte am Esch, Univ Krankenhauf Eppendorf, Hamburg Germany; S Nyberg, R H Wiesner, Mayo Clinic, Rochester, MN; C Broelsch, M Malago, Universitatsklinikum Essen, Essen Germany; A Kribben, J Lerut, Cliniques Universitaires St Luc, Brussels Brussels Belgium; P Laterre, Cliniques Universitaires St Luc, Brussels Belgium; M Salizzoni, B Lavezzo, San Giovanni Battista di Torino, Turin Italy; R Brown, J Emond, S Lobritto, New York Presbyterian Hosp, New York, NY; B de Hemptinne, F Colardyn, E Hoste, Universitair Zeikenhaus Ghent, Ghent Belgium; E Fagan, Rush Presbyterian, Chicago, IL; L McChesney, Univ of Toledo, Toledo, OH; M Muraca, Univ di Padova, Padova Italy; A Mas Ordeig, J Salmeron, Hosp Clinic Provincial de Barcelona, Barcelona Spain; J Rabkin, Oregon Health Sciences Univ, Portland, OR; D Pratt, New England Medical Ctr, Boston, MA; M de la Mata, J Montero, J Pozo, Hosp Reina Sofia, Cordova Spain; H Metselaar, Univ Hosp Rotterdam, Rotterdam, The Netherlands, Rotterdam Netherlands; G Everson, Univ of Colorado, Denver, CO; Z Pitkin, C Mullon, B Solomon, Circe Biomed, Lexington, MA; A Demetriou, Cedars Sinai Medical Ctr, Los Angeles, CA